LI
SGMO

Leap Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Leap Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-55,097
Closed -$499K – 560
2019
Q3 		$499K Buy
+55,097
New +$618K 0.25% 137

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leap Investments's SGMO Position: Q4 2019 in Review

Leap Investments sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2019, closing a stake of 55,097 shares — an estimated $499K sold.

Leap Investments first reported a position in SGMO in Q3 2019 and held it in 1 quarter. The position peaked at $499K in Q3 2019. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2019.

  • Leap Investments reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 55,097 SANGAMO THERAPEUTICS INC shares in Q4 2019, an estimated $499K.
  • Leap Investments first reported a position in SANGAMO THERAPEUTICS INC in Q3 2019 and held it in 1 quarter.
  • Leap Investments's SANGAMO THERAPEUTICS INC position peaked at $499K in Q3 2019.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.